Dosing & Uses
Dosage Forms & Strengths
Benign Prostatic Hypertrophy
0.4 mg PO once daily, 30 minutes after same meal each day; if response is inadequate after 2-4 weeks, may be increased to 0.8 mg once daily; if therapy is interrupted, should be resumed at 0.4 mg once daily
Bladder Outlet Obstruction
Relief of symptoms
0.4 mg PO once daily
Facilitation of stone expulsion
0.4 mg PO once daily; discontinued after successful expulsion (average, 1-2 weeks)
- CrCl ≥10 mL/min: Dosage adjustment not necessary
- CrCl <10 mL/min: Not studied
- Mild to moderate: Dosage adjustment not necessary
- Severe: Not studied
Safety and efficacy not established
Serious - Use Alternative
Significant - Monitor Closely
Orthostatic hypotension (6-19%)
Abnormal ejaculation (8-18%)
Back pain (7-8%)
Skin rash (7%)
Chest pain (4%)
Abdominal discomfort (2-3%)
Bitter taste (2-3%)
Decreased libido (1-2%)
Signs and symptoms of orthostasis, including syncope
Infrequent reports of dyspnea, palpitations, hypotension, atrial fibrillation, arrhythmia, and tachycardia
During cataract and glaucoma surgery, a variant of small pupil syndrome known as Intraoperative Floppy Iris Syndrome (IFIS) has been reported in association with alpha1 blocker therapy
Skin desquamation including reports of Stevens-Johnson syndrome, erythema multiforme, and dermatitis exfoliative
Constipation, vomiting, and epistaxis
Allergic-type reactions (eg, skin rash, urticaria, pruritus, angioedema, respiratory symptoms) have been reported with positive rechallenge
Use with caution in coronary artery disease, liver disease, general anesthesia
Orthostatic hypotension may occur
Priapism rarely reported
Prostatic cancer should be ruled out before therapy is initiated
May cause syncope (first-dose effect)
Discontinue if angina symptoms occur or worsen
Intraoperative floppy iris syndrome has been reported in patients receiving alpha1 blockers at time of cataract surgery; association is unclear
Patients with sulfa allergy have rarely developed allergic reaction; avoid use if previous sulfa allergy reactions have been life-threatening
Not for use as antihypertensive drug
Pregnancy & Lactation
Pregnancy category: B
Lactation: Women are unlikely to use drug
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Blocks alpha1a adrenergic receptor in smooth muscle of prostate, decreasing bladder neck and urethral resistance
Bioavailability: Fasting, 30%
Onset: 4-8 hr
Peak plasma time: With food, 6-7 hr; fasting, 4-5 hr
Protein bound: 90%
Vd: 0.2 L/kg or 16 L
Metabolized in liver
Metabolites: Glucuronide and sulfate conjugates (inactive)
Half-life: 14-15 hr
Excretion: Urine (76%), feces (21%)
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs